Cryopyrin-Associated Periodic Fever Syndrome and the Nervous System.

Area of Science:

• Autoinflammatory diseases
• Genetics of inflammasome activation
• Immunology of interleukin-1β

Background:

• Cryopyrin-associated periodic fever syndrome (CAPS) is a group of rare autoinflammatory disorders.
• It is characterized by mutations in the NLRP3 gene, leading to excessive interleukin-1β (IL-1β) production.
• Systemic and neurological manifestations include fever, rash, arthralgia, amyloidosis, headache, hearing loss, and meningitis.

Purpose of the Study:

• To review the molecular and clinical features of CAPS.
• To highlight current management strategies for CAPS.
• To emphasize the importance of early diagnosis and targeted therapy.

Main Methods:

• Literature review of molecular and clinical characteristics of CAPS.
• Analysis of treatment outcomes with IL-1β inhibitors.
• Review of licensed pharmacological therapies.

Main Results:

• NLRP3 gene mutations drive IL-1β overproduction, causing systemic inflammation in CAPS.
• Targeted therapies inhibiting IL-1β, including canakinumab and anakinra, demonstrate remarkable efficacy.
• Early diagnosis and timely intervention with IL-1β inhibitors are crucial for preventing long-term complications, including potential neuroprotection.

Conclusions:

• CAPS is a debilitating disorder stemming from NLRP3 mutations and IL-1β dysregulation.
• Effective IL-1 targeted therapies are available and vital for managing the condition.
• Prompt treatment is essential to prevent irreversible complications and improve patient outcomes.